Busslinger and colleagues [24] compared 225Ac-SibuDAB to 225Ac-PSMA-617 in murine models and found 225Ac-SibuDAB to be more effective at destroying PSMA-positive tumor xenografts, although 225Ac-SibuDAB also had higher retention in normal tissues. This evidence concerns the gene FOLH1 and neoplasm.